These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap. Ledwos N; Rosenblat JD; Blumberger DM; Castle DJ; McIntyre RS; Mulsant BH; Husain MI J Clin Psychopharmacol; 2022 Nov-Dec 01; 42(6):581-588. PubMed ID: 36193898 [TBL] [Abstract][Full Text] [Related]
7. Cessation and reduction in alcohol consumption and misuse after psychedelic use. Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460 [TBL] [Abstract][Full Text] [Related]
8. Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review. Schimmers N; Breeksema JJ; Smith-Apeldoorn SY; Veraart J; van den Brink W; Schoevers RA Psychopharmacology (Berl); 2022 Jan; 239(1):15-33. PubMed ID: 34812901 [TBL] [Abstract][Full Text] [Related]
9. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Johnson MW; Hendricks PS; Barrett FS; Griffiths RR Pharmacol Ther; 2019 May; 197():83-102. PubMed ID: 30521880 [TBL] [Abstract][Full Text] [Related]
10. Classical psychedelics for the treatment of depression and anxiety: A systematic review. Muttoni S; Ardissino M; John C J Affect Disord; 2019 Nov; 258():11-24. PubMed ID: 31382100 [TBL] [Abstract][Full Text] [Related]
11. Microdosing psychedelics: Motivations, subjective effects and harm reduction. Lea T; Amada N; Jungaberle H; Schecke H; Klein M Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967 [TBL] [Abstract][Full Text] [Related]
12. Psychedelics as a Treatment for Alzheimer's Disease Dementia. Vann Jones SA; O'Kelly A Front Synaptic Neurosci; 2020; 12():34. PubMed ID: 32973482 [TBL] [Abstract][Full Text] [Related]
13. On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review. Zeifman RJ; Singhal N; Breslow L; Weissman CR ACS Pharmacol Transl Sci; 2021 Apr; 4(2):436-451. PubMed ID: 33860173 [TBL] [Abstract][Full Text] [Related]
14. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Vollenweider FX; Kometer M Nat Rev Neurosci; 2010 Sep; 11(9):642-51. PubMed ID: 20717121 [TBL] [Abstract][Full Text] [Related]
15. New Paradigms of Old Psychedelics in Schizophrenia. Mahmood D; Alenezi SK; Anwar MJ; Azam F; Qureshi KA; Jaremko M Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631466 [TBL] [Abstract][Full Text] [Related]
16. Neuroimaging Correlates of Treatment Response with Psychedelics in Major Depressive Disorder: A Systematic Review. Kuburi S; Di Passa AM; Tassone VK; Mahmood R; Lalovic A; Ladha KS; Dunlop K; Rizvi S; Demchenko I; Bhat V Chronic Stress (Thousand Oaks); 2022; 6():24705470221115342. PubMed ID: 35936944 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. Andersen KAA; Carhart-Harris R; Nutt DJ; Erritzoe D Acta Psychiatr Scand; 2021 Feb; 143(2):101-118. PubMed ID: 33125716 [TBL] [Abstract][Full Text] [Related]
18. The therapeutic potential of microdosing psychedelics in depression. Kuypers KPC Ther Adv Psychopharmacol; 2020; 10():2045125320950567. PubMed ID: 32922736 [TBL] [Abstract][Full Text] [Related]
19. Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications. Kraehenmann R Curr Neuropharmacol; 2017; 15(7):1032-1042. PubMed ID: 28625125 [TBL] [Abstract][Full Text] [Related]
20. Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. Garcia-Romeu A; Richards WA Int Rev Psychiatry; 2018 Aug; 30(4):291-316. PubMed ID: 30422079 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]